Reuters logo
BRIEF-Txcell receives EU orphan drug designation for Col-Treg
December 17, 2014 / 5:01 PM / in 3 years

BRIEF-Txcell receives EU orphan drug designation for Col-Treg

Dec 17 (Reuters) - Txcell SA :

* Txcell receives EU orphan drug designation for Col-Treg in the treatment of non-infectious uveitis

* Placebo-Controlled, dose-ranging proof of principle clinical study in autoimmune uveitis for Col-Treg planned to start in H1 2015

* Topline results of principle clinical study in autoimmune uveitis for Col-Treg expected mid-2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below